secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2025-07-07T23:59:59+00:00
Accession:  0001213900-25-061632
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper reports 89% complete response in single-dose CSU cohorts, but drug lot issue delays Phase 2b to mid-2026
--------------------------------------------------------------------------------

- 8 of 9 (89%) patients in 240mg and 360mg single-dose cohorts achieved complete response (UAS7=0).
- 8 of 11 (73%) in 180mg Q8W open-label extension achieved complete response at week 12.
- Results from 240mg Q8W and 240mg→180mg Q8W cohorts confounded by drug product lot issue affecting 10 of 13 patients.
- ETESIAN asthma study halted due to same lot issue; SCID development stopped; cost cutting and potential restructuring.
- Additional BEACON data expected Q4 2025; Phase 2b CSU study start delayed to mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025061632/0001213900-25-061632-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025061632/ea0248252-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-061632

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer